BIO-TECHNE (TECH) Receiving Somewhat Positive News Coverage, Study Finds
Media stories about BIO-TECHNE (NASDAQ:TECH) have trended somewhat positive recently, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BIO-TECHNE earned a media sentiment score of 0.09 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 47.178924127245 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of BIO-TECHNE (TECH) traded down $0.31 during mid-day trading on Monday, reaching $142.01. 176,779 shares of the company’s stock were exchanged, compared to its average volume of 178,525. BIO-TECHNE has a 1 year low of $95.68 and a 1 year high of $143.64. The company has a market capitalization of $5,331.62, a PE ratio of 73.58, a PEG ratio of 3.21 and a beta of 0.75. The company has a current ratio of 2.87, a quick ratio of 2.25 and a debt-to-equity ratio of 0.35.
BIO-TECHNE (NASDAQ:TECH) last announced its quarterly earnings data on Tuesday, October 31st. The biotechnology company reported $0.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.82 by $0.08. BIO-TECHNE had a net margin of 12.54% and a return on equity of 14.11%. The firm had revenue of $144.61 million for the quarter, compared to analysts’ expectations of $142.37 million. During the same period last year, the firm earned $0.84 earnings per share. The business’s revenue for the quarter was up 10.7% on a year-over-year basis. analysts forecast that BIO-TECHNE will post 3.8 EPS for the current year.
In other BIO-TECHNE news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $130.18, for a total value of $650,900.00. Following the transaction, the director now directly owns 12,712 shares of the company’s stock, valued at $1,654,848.16. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.40% of the stock is currently owned by company insiders.
Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.
Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.